Novartis is responding to COVID-19 with the safety of our associates and patients we serve as our main concern. We continue to contribute to global research efforts, support local communities and ensure stable supply and price of essential medicines. This US information center provides updates, guidance and other resources.
Information update about the Novartis CAN-COVID trial
The CAN-COVID clinical trial has been one of the ways Novartis is drawing on its global resources and scientific expertise in response to the COVID-19 pandemic.